NEW YORK (GenomeWeb News) – Martin Madaus has been named as Quanterix's permanent CEO. Madaus, who is chairman of the company, had been serving as interim CEO since May when David Okrongly left the Cambridge, Mass.-based company.
Madaus has served as a director of Quanterix since 2010, and became chairman of the firm last December. Prior to joining Quanterix, he served as president, chairman, and CEO of Millipore before it was acquired by Merck KGaA last year. Before his tenure at Millipore, Madaus was president, CEO, and head of North American operations for Roche Diagnostics.
Kary Mullis, the Nobel prize-winning inventor of PCR, has entered into a new joint venture with Loxbridge Research to form Altermune Technologies, which will focus on developing therapeutics for pathogens such as methicillin-resistant Staphylococcus aureus, Clostridium difficile, pseudomonas, and pandemic influenza. Mullis will take on the role of chief scientific officer of Altermune. Charles Roberts, CEO of Loxbridge, will serve as president of Altermune during the initial development period. Loxbridge will provide milestone-based seed funding worth $7 million to Altermune.
Two of the 22 new 2011 MacArthur Fellows, an award from the John D. and Catherine T. MacArthur Foundation that provides a $500,000 prize, have focused their careers on molecular biology and genetics.
Elodie Ghedin is a professor of computational and systems biology at the University of Pittsburgh School of Medicine, and Sara Otto is a theoretical biologist and professor of Zoology at the University of British Columbia.
Ghedin, also an investigator at the J. Craig Venter institute, has led international projects to study virulent human pathogens, such as leishmaniasis and sleeping sickness, and has used genome sequencing and analysis to show how viruses evolve within geographic regions. According to the MacArthur Foundation, Ghedin has demonstrated that molecular genetics is essential for exploring pathogen biology and is a powerful tool for use in global public health.
Otto's research has focused on population genetics and evolution. She has studied the evolutionary causes of diploidy and the benefits of sexual and asexual reproduction.
Diagnostics company CardioDx has hired Andrew Guggenhime to be its chief financial officer and Mark Monane to be its chief medical officer. Guggenhime formerly was senior VP and CEO of Facet Biotech, which was bought by Abbott Laboratories last year, and he was CFO for Calistoga Pharmaceuticals. Monane was managing director of equity research at Needham and Co. and he was a senior director at Medco Health Solutions and an assistant professor at Harvard Medical School and the School of Public Health.
Selventa CEO David de Graaf has been selected to serve on the scientific advisory board of the Massachusetts Institute of Technology's Center for Cancer Systems Biology. MIT's CCSB is one of 10 formed under the National Cancer Institute's Integrative Cancer Biology Program that focus on developing and implementing computational models to analyze cancer as a complex biological system.
Swedish testing firm Cellectricon has appointed David Burns to be company CEO and president. Burns has worked in senior management positions at GE Healthcare, Renishaw Diagnostics, Cyntellect, BioSignal Packard, and Pharmacia.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.